• In early May 2026, Crinetics Pharmaceuticals reported first-quarter revenue of about US$10.73 million, up sharply from roughly US$0.36 million a year earlier, alongside a wider net loss of about US$127.85 million and basic loss per share of US$1.23.
• Shortly before these results, the European Commission approved PALSONIFY (paltusotine) as the first once-daily oral therapy for adult acromegaly across the EU and EEA, reinforcing Crinetics’ shift into a commercial-stage rare disease business with expanding global reach.
• With PALSONIFY now approved in both the U.S. and EU and generating initial product revenue, we’ll examine how this reshapes Crinetics’ investment narrative.

Find 50 companies with promising cash flow potential yet trading below their fair value.

Crinetics Pharmaceuticals Investment Narrative Recap

To own Crinetics today, you need to believe that PALSONIFY can become a meaningful, durable therapy in acromegaly while the broader endocrine pipeline gradually adds follow on indications. The latest quarter confirms rising product revenue but also highlights a widening net loss, so the key near term catalyst is continued U.S. prescription growth, while the biggest risk is that high operating expenses persist without a matching ramp in PALSONIFY uptake. The new EU approval does not change that risk, but it broadens the opportunity set.

Among the recent developments, the European Commission approval of PALSONIFY stands out as most relevant. It validates the Phase 3 data package in a second major region and opens access across the EU and EEA, with initial commercialization focused on Germany and Austria. For investors watching catalysts, this adds a future source of product revenue on top of early U.S. sales and interacts directly with concerns about how quickly Crinetics can offset its sizable quarterly losses.

However, investors should also be aware that if operating costs stay high while international PALSONIFY sales build more slowly than hoped, the cash runway could...

Crinetics Pharmaceuticals' narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This requires 566.4% yearly revenue growth and a $517.9 million earnings increase from -$423.1 million today.

Uncover how Crinetics Pharmaceuticals' forecasts yield a $82.43 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$534.2 million by 2028, which is far more aggressive than the baseline narrative and leans heavily on the idea that PALSONIFY’s launch, including early EU traction, overcomes concerns about cash burn and market size, so it is worth comparing that view with your own expectations in light of Crinetics’ latest US$10.73 million quarter.

Explore 4 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.